Hong Kong talks legal action after ordering GSK recall
The Hong Kong Department of Health (DH) has ordered GlaxoSmithKline (GSK) to recall the product, Augmentin 375mg tablets and is seeking legal advice. The DH is consulting with colleagues at the Department of Justice to determine “possible legal actions against GSK”.
Action to stop of Augmentin 375mg tablets reaching patients follows a recall of the same product in powder for syrup form. Following the first recall the Hong Kong Department of Health placed GSK under “enhanced surveillance”, leading to detection of plasticisers in the tablets.
"Since GSK could not provide satisfactory explanation on sources of the plasticisers, the quality of the product is in question", said a spokesman for the DH.
Testing has so far failed to determine the source of the of the plasticisers and an investigation is ongoing. The levels of plasticisers “are considered unlikely to cause acute harmful effects” at normal dosage levels, said the DH.
